AU2006301578B9 - Method for diagnosing thromboembolic disorders and coronary heart diseases - Google Patents
Method for diagnosing thromboembolic disorders and coronary heart diseases Download PDFInfo
- Publication number
- AU2006301578B9 AU2006301578B9 AU2006301578A AU2006301578A AU2006301578B9 AU 2006301578 B9 AU2006301578 B9 AU 2006301578B9 AU 2006301578 A AU2006301578 A AU 2006301578A AU 2006301578 A AU2006301578 A AU 2006301578A AU 2006301578 B9 AU2006301578 B9 AU 2006301578B9
- Authority
- AU
- Australia
- Prior art keywords
- group
- coronary heart
- egln2
- determined
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 30
- 230000009424 thromboembolic effect Effects 0.000 title claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 13
- 208000035475 disorder Diseases 0.000 title description 2
- 101000881650 Homo sapiens Prolyl hydroxylase EGLN2 Proteins 0.000 claims abstract description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 19
- 239000002773 nucleotide Substances 0.000 claims abstract description 19
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 19
- 102000048660 human EGLN2 Human genes 0.000 claims abstract description 18
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 10
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 10
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 102100037248 Prolyl hydroxylase EGLN2 Human genes 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 208000010125 myocardial infarction Diseases 0.000 claims description 18
- 208000001435 Thromboembolism Diseases 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 239000000523 sample Substances 0.000 claims description 16
- 208000006011 Stroke Diseases 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 11
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 6
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 210000002889 endothelial cell Anatomy 0.000 claims description 5
- 229940104230 thymidine Drugs 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 206010050496 Reversible ischaemic neurological deficit Diseases 0.000 claims description 3
- 239000013611 chromosomal DNA Substances 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 238000003203 nucleic acid sequencing method Methods 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 238000002965 ELISA Methods 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 238000002105 Southern blotting Methods 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 238000012175 pyrosequencing Methods 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Natural products O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 230000007614 genetic variation Effects 0.000 description 5
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 description 4
- 102200148363 rs672601362 Human genes 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 3
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 description 3
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 3
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 3
- 101710170760 Prolyl hydroxylase EGLN2 Proteins 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000020874 response to hypoxia Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101710111663 Egl nine homolog 1 Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710170720 Prolyl hydroxylase EGLN3 Proteins 0.000 description 1
- 244000078856 Prunus padus Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000019039 oxygen homeostasis Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005048899.4 | 2005-10-12 | ||
| DE102005048899A DE102005048899A1 (de) | 2005-10-12 | 2005-10-12 | Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| PCT/EP2006/009517 WO2007042165A1 (de) | 2005-10-12 | 2006-09-30 | Verfahren zur diagnose thromboembolischer erkrankungen und koronarer herzerkrankungen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2006301578A1 AU2006301578A1 (en) | 2007-04-19 |
| AU2006301578B2 AU2006301578B2 (en) | 2011-12-01 |
| AU2006301578B9 true AU2006301578B9 (en) | 2011-12-22 |
Family
ID=37684083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006301578A Withdrawn - After Issue AU2006301578B9 (en) | 2005-10-12 | 2006-09-30 | Method for diagnosing thromboembolic disorders and coronary heart diseases |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090197774A1 (enExample) |
| EP (1) | EP1937839B1 (enExample) |
| JP (1) | JP2009511026A (enExample) |
| KR (1) | KR20080052662A (enExample) |
| CN (1) | CN101287846A (enExample) |
| AR (1) | AR056125A1 (enExample) |
| AT (1) | ATE525481T1 (enExample) |
| AU (1) | AU2006301578B9 (enExample) |
| BR (1) | BRPI0617341A2 (enExample) |
| CA (1) | CA2625698A1 (enExample) |
| DE (1) | DE102005048899A1 (enExample) |
| IL (1) | IL190585A (enExample) |
| TW (1) | TW200734638A (enExample) |
| WO (1) | WO2007042165A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005048898A1 (de) * | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen |
| EP2311981B1 (en) | 2007-05-01 | 2014-09-17 | The Regents of The University of California | Methods for diagnosing ischemia |
| US20120015904A1 (en) * | 2010-07-14 | 2012-01-19 | Regents Of The University Of California | Biomarkers for diagnosis of transient ischemic attacks |
| CA2804802C (en) | 2010-07-15 | 2023-03-07 | The Regents Of The University Of California | Biomarkers for diagnosis of stroke and its causes |
| US20120316076A1 (en) | 2011-03-04 | 2012-12-13 | The Regents Of The University Of California | Biomarkers for the diagnosis of lacunar stroke |
| CA2856461C (en) * | 2011-12-01 | 2020-08-18 | F. Hoffmann-La Roche Ag | Nt-proanp and nt-probnp for the diagnosis of stroke |
| WO2013103781A1 (en) | 2012-01-07 | 2013-07-11 | The Regents Of The University Of California | Biomarkers for diagnosing ischemia |
| KR101939778B1 (ko) | 2012-07-27 | 2019-01-18 | 삼성전자주식회사 | 필요 혈류량 결정 방법 및 장치, 혈류 영상 생성 방법 및 장치, 심근 관류 영상 처리 방법 및 장치 |
| CN119846215B (zh) * | 2025-01-22 | 2025-07-11 | 广西医科大学附属肿瘤医院 | Egln1乳酸化作为靶点在制备肿瘤诊断试剂盒或治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2474630B1 (en) * | 2002-12-20 | 2016-04-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| CA2510895A1 (en) * | 2002-12-20 | 2004-07-15 | Applera Corporation | Genetic polymorphisms associated with stenosis, methods of detection and uses thereof |
-
2005
- 2005-10-12 DE DE102005048899A patent/DE102005048899A1/de not_active Withdrawn
-
2006
- 2006-09-30 US US12/089,624 patent/US20090197774A1/en not_active Abandoned
- 2006-09-30 JP JP2008534895A patent/JP2009511026A/ja not_active Abandoned
- 2006-09-30 WO PCT/EP2006/009517 patent/WO2007042165A1/de not_active Ceased
- 2006-09-30 BR BRPI0617341-1A patent/BRPI0617341A2/pt not_active Application Discontinuation
- 2006-09-30 CA CA002625698A patent/CA2625698A1/en not_active Withdrawn
- 2006-09-30 EP EP06792341A patent/EP1937839B1/de not_active Not-in-force
- 2006-09-30 AT AT06792341T patent/ATE525481T1/de active
- 2006-09-30 KR KR1020087008790A patent/KR20080052662A/ko not_active Withdrawn
- 2006-09-30 AU AU2006301578A patent/AU2006301578B9/en not_active Withdrawn - After Issue
- 2006-09-30 CN CNA2006800376009A patent/CN101287846A/zh active Pending
- 2006-10-05 TW TW095136992A patent/TW200734638A/zh unknown
- 2006-10-10 AR ARP060104446A patent/AR056125A1/es unknown
-
2008
- 2008-04-02 IL IL190585A patent/IL190585A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101287846A (zh) | 2008-10-15 |
| TW200734638A (en) | 2007-09-16 |
| AR056125A1 (es) | 2007-09-19 |
| IL190585A0 (en) | 2008-11-03 |
| AU2006301578B2 (en) | 2011-12-01 |
| ATE525481T1 (de) | 2011-10-15 |
| WO2007042165A1 (de) | 2007-04-19 |
| US20090197774A1 (en) | 2009-08-06 |
| AU2006301578A1 (en) | 2007-04-19 |
| EP1937839A1 (de) | 2008-07-02 |
| CA2625698A1 (en) | 2007-04-19 |
| JP2009511026A (ja) | 2009-03-19 |
| EP1937839B1 (de) | 2011-09-21 |
| DE102005048899A1 (de) | 2007-04-19 |
| IL190585A (en) | 2011-12-29 |
| BRPI0617341A2 (pt) | 2011-07-26 |
| KR20080052662A (ko) | 2008-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12065702B2 (en) | Mitochondrial markers of neurodegenerative diseases | |
| IL190585A (en) | Method for the diagnosis of thromboembolic and coronary heart diseases | |
| JP4516990B2 (ja) | ワルファリンの投与量の範囲を予想する方法 | |
| WO2001053537A2 (en) | Nitric oxide synthase gene diagnostic polymorphisms | |
| CN100549173C (zh) | 具有特定单核苷酸多态性的th基因及其检测方法和用途 | |
| CA2675606A1 (en) | Diagnostic marker and platform for drug design in myocardial infarction and heart failure | |
| EP1960543B1 (en) | Method for the diagnosis and treatment of cardiovascular diseases | |
| US9909182B1 (en) | Methods for identifying subjects susceptible to charcot-marie-tooth neuropathy type 1C | |
| JP3682688B2 (ja) | 骨粗鬆症薬剤感受性予測方法およびそのための試薬キット | |
| JP4444576B2 (ja) | ２型糖尿病関連遺伝子 | |
| CN102443630A (zh) | 人ppp2r3a基因突变及其用途 | |
| JP2003245087A (ja) | 遺伝子診断方法 | |
| HK1125414A (en) | Method for diagnosing thromboembolic disorders and coronary heart diseases | |
| JP4845486B2 (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 | |
| JP4048555B2 (ja) | 骨粗鬆症薬剤感受性予測方法 | |
| JP5235448B2 (ja) | 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法 | |
| JP3684921B2 (ja) | 骨粗鬆症薬剤感受性予測方法 | |
| WO2006073183A1 (ja) | 一塩基多型を用いた炎症性疾患の判定方法 | |
| JPWO2006068111A1 (ja) | ＰＰＡＲγ遺伝子の遺伝子多型に関連する表現型の判定方法 | |
| WO2002006522A2 (en) | Estrogen receptor gene polymorphisms as markers for determining a predisposition for low bone density | |
| NZ564717A (en) | Marker assisted selection of bovine for desired milk fat colour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished | ||
| MK12 | Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal |